The University of Kansas Cancer Center requests CCSG funds for developmental funds to be specifically used for the pilot studies program and to supplement new recruitment packages. The major purpose of the Pilot Studies Program is to provide support for highly innovative research proposals in new, exciting, and potentially breakthrough areas of cancer research. The pilot research proposal must be cancer-related and must not overlap with existing funding from any source (different focus and different aims). Ultimately, the goal is to have these funds provide critical preliminary data to test new hypotheses and assess feasibility of ideas that might allow for rapid advancement in the field and make an impact in basic, clinical, or translational research. The merit of these proposals will be assessed by members of the KUCC-Leadership Council and approved by the Director prior to funding. To actively build and improve our research environment, KUCC is committed to recruiting additional cancer researchers to increase the national and international status of the Cancer Center, enhance the number of NCI/cancer-related grants, fill critical research positions and build the four cancer research programs. Each purposeful hire aims to further the scientific vision, mission, and goals of the Cancer Center research programs. The funds requested will be used to supplement the recruitment packages of future cancer center recruits and will be leveraged by matching with Kansas Bioscience Authority funds.

Public Health Relevance

The University of Kansas Cancer Center plans to utilize developmental funds to continue and to supplement its highly successful pilot project program to provide funding to test new research ideas. In addition, we will use a portion of the funds to supplement recruitment packages for new investigators.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Kansas
Kansas City
United States
Zip Code
Ledgerwood, Levi G; Kumar, Dhruv; Eterovic, Agda Karina et al. (2016) The degree of intratumor mutational heterogeneity varies by primary tumor sub-site. Oncotarget 7:27185-98
Reed, Gregory A; Schiller, Gary J; Kambhampati, Suman et al. (2016) A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia. Cancer Med 5:3031-3040
Chen, Fengju; Zhang, Yiqun; ÅženbabaoÄŸlu, Yasin et al. (2016) Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Rep 14:2476-89
Parsel, S M; Grandis, J R; Thomas, S M (2016) Nucleic acid targeting: towards personalized therapy for head and neck cancer. Oncogene 35:3217-26
(2016) Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun 7:12675
Mitchell, Julie L; Seng, Amara; Yankee, Thomas M (2016) Expression patterns of Ikaros family members during positive selection and lineage commitment of human thymocytes. Immunology 149:400-412
Hamilton-Reeves, Jill M; Bechtel, Misty D; Hand, Lauren K et al. (2016) Effects of Immunonutrition for Cystectomy on Immune Response and Infection Rates: A Pilot Randomized Controlled Clinical Trial. Eur Urol 69:389-92
Kurahara, Hiroshi; Bohl, Christopher; Natsugoe, Shoji et al. (2016) Suppression of pancreatic cancer growth and metastasis by HMP19 identified through genome-wide shRNA screen. Int J Cancer 139:628-38
Jiang, Yu; Guarino, Peter; Ma, Shuangge et al. (2016) Bayesian accrual prediction for interim review of clinical studies: open source R package and smartphone application. Trials 17:336
(2016) No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol 141:386-401

Showing the most recent 10 out of 93 publications